Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Sun Pharmaceutical Industries Ltd. 524715 shares slid 1.14% to 1,779.30 Indian rupees Wednesday, on what proved to be an all-around poor trading session for the stock market, with the BSE SENSEX Index ...

Dilip Shanghvi's journey from the beginning with just Rs 2,000 highlights the importance of resilience, adaptability, and ...

Brand-heavy companies such as Mankind Pharma, Sun Pharma, Torrent Pharmaceuticals and Eris Lifesciences are expected to ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Sun Pharma is set to announce its Q2 FY25 results, with revenue growth expected to be driven by domestic business and higher ...

India's Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of hair loss.

The company's EBITDA stood at Rs. 3939.0 crore (including other operating revenues), up 23.9 percent, with resulting EBITDA margin of 29.6 percent.

What is the Sun Pharmaceuticals Industries Ltd share price today? The Sun Pharmaceuticals Industries Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1809.6 today. What is the Market Cap of ...